Evidence map›Paper›PMID 15103507›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2004

Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations.

Nanda C Krak, Otto S Hoekstra, Adriaan A Lammertsma

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nanda C KrakDepartment of Nuclear Medicine and PET Research, VU University Medical Centre, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands.
Otto S Hoekstra
Adriaan A Lammertsma

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this review the findings of response monitoring studies in breast cancer, using [(18)F]2-fluoro-2-deoxy-D-glucose (FDG) and positron emission tomography (PET), are summarised. These studies indicate that there is a strong relationship between response and decrease in FDG signal even at an early stage of therapy. The review concentrates on methodological aspects of monitoring response with FDG: timing of serial scans, approach to region of interest definition, method of quantification and pitfalls of FDG. It is argued that, for clinical applications, there is now a need to standardise methodology. This would be necessary to establish firm cut-off values for discriminating responders from non-responders, which in turn would provide a means for providing optimal treatment for as many patients as possible.

Indexed as

Decision Support Systems, ClinicalFluorodeoxyglucose F18Antineoplastic AgentsBreast NeoplasmsClinical Trials as TopicFemaleHumansImage Interpretation, Computer-AssistedLymphatic MetastasisLymph NodesNeoplasm StagingPositron-Emission TomographyPractice Guidelines as TopicPractice Patterns, Physicians'PrognosisRadiopharmaceuticalsAntineoplastic AgentsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID15103507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.